PI3K signalling / / topic editors, Klaus Okkenhaug, Martin Turner and Michael R. Gold.

The PI3Ks control many key functions in immune cells. PI3Ks phosphorylate PtdIns(4,5)P2 to yield PtdIns(3,4,5)P3. Initially, PI3K inhibitors such as Wortmannin, LY294002 and Rapamycin were used to establish a central role for Pi3K pathway in immune cells. Considerable progress in understanding the r...

Full description

Saved in:
Bibliographic Details
:
TeilnehmendeR:
Place / Publishing House:[Lausanne, Switzerland] : : Frontiers Media SA,, 2015.
Year of Publication:2015
Language:English
Series:Frontiers Research Topics,
Physical Description:1 online resource (139 pages).
Tags: Add Tag
No Tags, Be the first to tag this record!
id 993547653404498
ctrlnum (CKB)3710000000526106
(WaSeSS)IndRDA00057317
(oapen)https://directory.doabooks.org/handle/20.500.12854/56255
(EXLCZ)993710000000526106
collection bib_alma
record_format marc
spelling Martin Turner auth
PI3K signalling / topic editors, Klaus Okkenhaug, Martin Turner and Michael R. Gold.
Frontiers Media SA 2015
[Lausanne, Switzerland] : Frontiers Media SA, 2015.
1 online resource (139 pages).
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
Frontiers Research Topics, 1664-8714
Includes bibliographical references.
Description based on: online resource; title from pdf title page (frontiers, viewed Jun. 8, 2016).
The PI3Ks control many key functions in immune cells. PI3Ks phosphorylate PtdIns(4,5)P2 to yield PtdIns(3,4,5)P3. Initially, PI3K inhibitors such as Wortmannin, LY294002 and Rapamycin were used to establish a central role for Pi3K pathway in immune cells. Considerable progress in understanding the role of this pathway in cells of the immune system has been made in recent years, starting with analysis of various PI3K and Pten knockout mice and subsequently mTOR and Foxo knockout mice. Together, these experiments have revealed how PI3Ks control B cell and T cell development, T helper cell differentiation, regulatory T cell development and function, B cell and T cell trafficking, immunoglobulin class switching and much, much more. The PI3Kd inhibitor idelalisib has recently been approved for the treatment of B cell lymphoma. Clinical trials of other PI3K inhibitors in autoimmune and inflammatory diseases are also in progress. This is an opportune time to consider a Research Topic considering when what we have learned about the PI3K signalling module in lymphocyte biology and how this is making an impact on clinical immunology and haematology.
English
Immunologic diseases.
B cell
PI3K/AKT/mTOR
Signal Transduction
T cell
PI3K pathway inhibitors
2-88919-419-1
Okkenhaug, Klaus, editor.
Turner, Martin, editor.
Gold, Michael R., editor.
language English
format eBook
author Martin Turner
spellingShingle Martin Turner
PI3K signalling /
Frontiers Research Topics,
author_facet Martin Turner
Okkenhaug, Klaus,
Turner, Martin,
Gold, Michael R.,
author_variant m t mt
author2 Okkenhaug, Klaus,
Turner, Martin,
Gold, Michael R.,
author2_variant k o ko
m t mt
m r g mr mrg
author2_role TeilnehmendeR
TeilnehmendeR
TeilnehmendeR
author_sort Martin Turner
title PI3K signalling /
title_full PI3K signalling / topic editors, Klaus Okkenhaug, Martin Turner and Michael R. Gold.
title_fullStr PI3K signalling / topic editors, Klaus Okkenhaug, Martin Turner and Michael R. Gold.
title_full_unstemmed PI3K signalling / topic editors, Klaus Okkenhaug, Martin Turner and Michael R. Gold.
title_auth PI3K signalling /
title_new PI3K signalling /
title_sort pi3k signalling /
series Frontiers Research Topics,
series2 Frontiers Research Topics,
publisher Frontiers Media SA
Frontiers Media SA,
publishDate 2015
physical 1 online resource (139 pages).
isbn 2-88919-419-1
issn 1664-8714
callnumber-first R - Medicine
callnumber-subject RC - Internal Medicine
callnumber-label RC582
callnumber-sort RC 3582
illustrated Not Illustrated
work_keys_str_mv AT martinturner pi3ksignalling
AT okkenhaugklaus pi3ksignalling
AT turnermartin pi3ksignalling
AT goldmichaelr pi3ksignalling
status_str n
ids_txt_mv (CKB)3710000000526106
(WaSeSS)IndRDA00057317
(oapen)https://directory.doabooks.org/handle/20.500.12854/56255
(EXLCZ)993710000000526106
carrierType_str_mv cr
is_hierarchy_title PI3K signalling /
author2_original_writing_str_mv noLinkedField
noLinkedField
noLinkedField
_version_ 1796651906639069184
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01282nam a2200325 i 4500</leader><controlfield tag="001">993547653404498</controlfield><controlfield tag="005">20160608103058.0</controlfield><controlfield tag="006">m o u </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">160608s2015 sz |||||o|||||||||||eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)3710000000526106</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(WaSeSS)IndRDA00057317</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/56255</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)993710000000526106</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">WaSeSS</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">WaSeSS</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC582</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Martin Turner</subfield><subfield code="4">auth</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">PI3K signalling /</subfield><subfield code="c">topic editors, Klaus Okkenhaug, Martin Turner and Michael R. Gold.</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="b">Frontiers Media SA</subfield><subfield code="c">2015</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">[Lausanne, Switzerland] :</subfield><subfield code="b">Frontiers Media SA,</subfield><subfield code="c">2015.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (139 pages).</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Frontiers Research Topics,</subfield><subfield code="x">1664-8714</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references.</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on: online resource; title from pdf title page (frontiers, viewed Jun. 8, 2016).</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The PI3Ks control many key functions in immune cells. PI3Ks phosphorylate PtdIns(4,5)P2 to yield PtdIns(3,4,5)P3. Initially, PI3K inhibitors such as Wortmannin, LY294002 and Rapamycin were used to establish a central role for Pi3K pathway in immune cells. Considerable progress in understanding the role of this pathway in cells of the immune system has been made in recent years, starting with analysis of various PI3K and Pten knockout mice and subsequently mTOR and Foxo knockout mice. Together, these experiments have revealed how PI3Ks control B cell and T cell development, T helper cell differentiation, regulatory T cell development and function, B cell and T cell trafficking, immunoglobulin class switching and much, much more. The PI3Kd inhibitor idelalisib has recently been approved for the treatment of B cell lymphoma. Clinical trials of other PI3K inhibitors in autoimmune and inflammatory diseases are also in progress. This is an opportune time to consider a Research Topic considering when what we have learned about the PI3K signalling module in lymphocyte biology and how this is making an impact on clinical immunology and haematology.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Immunologic diseases.</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">B cell</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PI3K/AKT/mTOR</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Signal Transduction</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">T cell</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PI3K pathway inhibitors</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">2-88919-419-1</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Okkenhaug, Klaus,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Turner, Martin,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gold, Michael R.,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-02-22 20:29:15 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2015-12-12 16:57:58 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&amp;portfolio_pid=5338608580004498&amp;Force_direct=true</subfield><subfield code="Z">5338608580004498</subfield><subfield code="b">Available</subfield><subfield code="8">5338608580004498</subfield></datafield></record></collection>